short-term administration ( 8 weeks ) of ok-432 subcutaneously before , during , or after bbn did not affect bladder carcinogenesis , but if ok-432 was begun after bbn and continued until the end of the experiment , the incidence of bbn-induced bladder tumor was significantly reduced .
C0005682
bladder
C0005695
the